Skip to main content

Advertisement

SpringerLink
Log in

Complications of Botox and their Management

  • Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Adherence to anticholinergic medications is known to be a problem in patients with overactive bladder, with only 13.2% of patients continuing anticholinergic therapy beyond 1 year D’Souza et al. (J Manag Care Pharm. 14:291-301, 2008).

Recent Findings

Prior to the advent of third line therapies such as onabotulinumtoxin A, refractory overactive bladder (OAB) was managed with augmentation cystoplasty, a lengthy surgery with associated side effects including lifetime need for self-catheterization, ileus, and metabolic disturbances. The advent of onabotulinumtoxin A has drastically reduced the rates of augmentation cystoplasties being performed for refractory OAB. However, all procedures are associated with side effects which should be relayed to the patient prior to beginning therapy, as well as their management.

Summary

In the current review, we summarize the common complications following onabotulinumtoxin A injection as well as their management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188:2455–63.

    Article  PubMed  Google Scholar 

  2. Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249–56.

    Article  CAS  PubMed  Google Scholar 

  3. Cruz F, Herschorn S, Aliota P. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742–50.

    Article  CAS  PubMed  Google Scholar 

  4. Ginsberg DA, Drake MJ, Kaufmann A, Radomski S, Gousse AE, Chermansky CJ, et al. Long-term treatment with onabotulinumtoxinA results in consistent, durable improvements in health related quality of life in patients with overactive bladder. J Urol. 2017;198:897–904.

    Article  CAS  PubMed  Google Scholar 

  5. Osborn DJ, Kaufman MR, Mock S, Guan MJ, Dmochowski RR, Reynolds WS. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34:675–8.

    Article  CAS  PubMed  Google Scholar 

  6. Liberman D, Milhouse O, Johnson-Mitchell M, et al. Real-world retention rates after intravesical onabotulinumtoxina for idiopathic overactive bladder. Female Pelvic Med Reconstr Surg. 2017. https://doi.org/10.1097/SPV.0000000000000496.

  7. Kennelly M, Green L, Alvandi N, et al. Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings. Curr Med Res Opin. 2018;20:1–6.

    Google Scholar 

  8. Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, Placebo Controlled Trial. J Urol. 2017;197:S216–23.

    Article  CAS  PubMed  Google Scholar 

  9. Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196(3):791–800.

    Article  CAS  PubMed  Google Scholar 

  10. Patel DN, Jamnagerwalla J, Houman J, Anger JT, Eilber KS. What is the true catheterization rate after intravesical onabotulinumtoxinA injection? Int Urogynecol J. 2018;29:1005–9.

    Article  PubMed  Google Scholar 

  11. Jiang YH, Ong HL, Kuo HC. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-a real-life practice of 290 cases in a single center. Neurourol Urodyn. 2017;36:142–7.

    Article  CAS  PubMed  Google Scholar 

  12. Everaert K, Gruenenfelder J, Schulte-Bakloh H, et al. Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: a pooled analysis of two randomized controlled trials. Int J Urol. 2015;22:1131–7.

    Article  CAS  PubMed  Google Scholar 

  13. Kennelly M, Dmochowski R, Schulte-Bakloh H, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2017;36:368–75.

    Article  CAS  PubMed  Google Scholar 

  14. Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther. 2013;30:819–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. BOTOX (onabotulinumtoxin A) for injection, for intramuscular, intradetrusor, or intradermal use: Food and Drug Administration, 2017.

  16. Cheng T, Shuang WB, Jia DD, Zhang M, Tong XN, Yang WD, et al. Efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2016;11:e0159307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018;74:66–73.

    Article  CAS  PubMed  Google Scholar 

  18. Komesu YM, Amundsen CL, Richter HE. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol. 2018;218:111.e1–111.

    Article  Google Scholar 

  19. Zhou X, Yan HL, Cui YS, et al. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J. 2015;128(7):963–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chen SF, Chang CH, Kuo HC. Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: a clinical and immunohistochemistry study before and after treatment. Spinal Cord. 2016;54(10):889–94.

    Article  PubMed  Google Scholar 

  21. Kaufman MR. Botulinum Toxin Injection. In: Goldman HB, editor. Complications of female incontinence and pelvic reconstructive surgery. Cham: Springer International Publishing; 2017. p. 317–25.

    Chapter  Google Scholar 

  22. Weckx F, Tutolo M, De Ridder D, et al. The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol. 2016;5(1):63–71.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Vermont Medical Center, 792 College Parkway Ste. 101, Colchester, VT, 05446, USA

    Rose Leu & Gillian L. Stearns

Authors
  1. Rose Leu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian L. Stearns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian L. Stearns.

Ethics declarations

Conflict of Interest

Rose Leu and Gillian L. Stearns each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lower Urinary Tract Symptoms & Voiding Dysfunction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leu, R., Stearns, G.L. Complications of Botox and their Management. Curr Urol Rep 19, 90 (2018). https://doi.org/10.1007/s11934-018-0844-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-018-0844-6

Keywords

Search

Navigation